{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:25:51Z","timestamp":1794050751714,"version":"4.8.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Gout is associated with significant morbidity and mortality, yet suboptimal gout control remains a problem globally. Identifying the risk factors associated with poor gout control among patients in primary care allows targeted interventions to improve their clinical management. This study aimed to determine the prevalence of poor gout control and its associated demographic and clinical factors among urbanized community-dwelling Asian patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study was based on data extracted from the electronic medical records of 8 public primary care clinics in Singapore. Patients with a diagnostic code of gout who had 2 or more visits between 1st January 2018 and 31st December 2019 were included in the analysis. Data extracted included: demographics, anthropological measurements, comorbidities, serum uric acid levels and medication prescription. A patient is defined to have poor gout control if they suffer two or more acute gout attacks within a year. Chi-Squared test was used for categorical parameters. For continuous variables, univariate logistic regression analysis was first performed. Significant factors (<jats:italic>p<\/jats:italic> \u2264\u20090.1) were then included in the logistics regression model to account for confounders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 7,970 patients and 24,624 visits were included in the analysis. The prevalence of poorly controlled gout was 28.2% (<jats:italic>n<\/jats:italic> =\u20092,244\/7,970); only 46.3% of them (<jats:italic>n<\/jats:italic> =\u20091,039\/2,244) were prescribed allopurinol and 13.4% (<jats:italic>n<\/jats:italic> =\u2009301\/2,244) were taking doses \u2265300\u2009mg. Using logistic regression, factors associated with poor gout control were: male gender [adjusted OR (AOR) =1.66, <jats:italic>p<\/jats:italic> &amp;lt;\u20090.001], Malay ethnicity (AOR\u2009=\u20091.27, <jats:italic>p<\/jats:italic> =\u20090.007), congestive heart failure (AOR\u2009=\u20091.64, <jats:italic>p<\/jats:italic> =\u20090.037). Patients prescribed allopurinol (AOR\u2009=\u20091.52, <jats:italic>p<\/jats:italic> &amp;lt;\u20090.001), NSAIDs (AOR\u2009=\u20092.76, <jats:italic>p<\/jats:italic> &amp;lt;\u20090.001) and corticosteroids (AOR\u2009=\u20092.83, <jats:italic>p<\/jats:italic> &amp;lt;\u20090.001) were more likely to have poorly-controlled gout.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Nearly 30% of patients had poor gout. Interventions should focus on male and Malay patients and those with congestive cardiac failure.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1253839","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T17:14:26Z","timestamp":1694106866000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Epidemiology and risk factors associated with gout control among adult Asians: a real-world retrospective cohort study"],"prefix":"10.3389","volume":"10","author":[{"given":"Prawira","family":"Oka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Ming","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding Xuan","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Keong","family":"Aau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngiap Chuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence and risk factors","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/ard.2011.200523","article-title":"Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese health study","volume":"71","author":"Teng","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.rdc.2014.01.003","article-title":"Clinical manifestations and diagnosis of gout","volume":"40","author":"Perez-Ruiz","year":"2014","journal-title":"Rheum Dis Clin N Am"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"ii9","DOI":"10.1093\/rheumatology\/kep087","article-title":"Treating to target: a strategy to cure gout","volume":"48","author":"Perez-Ruiz","year":"2009","journal-title":"Rheumatology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3899\/jrheum.160452","article-title":"Serum uric acid and the risk of incident and recurrent gout: a systematic review","volume":"44","author":"Shiozawa","year":"2017","journal-title":"J Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/00325481.2016.1113840","article-title":"A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift","volume":"128","author":"Khanna","year":"2016","journal-title":"Postgrad Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1136\/ard-2022-222668","article-title":"Serum urate outcomes of treat-to-target urate lowering treatment: results of a nationwide cohort study from 1997 to the COVID-19 pandemic using data from the clinical practice research datalink","volume":"81","author":"Abhishek","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"100416","DOI":"10.1016\/j.lanepe.2022.100416","article-title":"Management of gout following 2016\/2017 European (EULAR) and British (BSR) guidelines: an interrupted time-series analysis in the United Kingdom","volume":"18","author":"Russell","year":"2022","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00296-019-04475-6","article-title":"Burden and management of gout in a multi-ethnic Asian cohort","volume":"40","author":"Chua","year":"2020","journal-title":"Rheumatol Int"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1007\/s10067-021-05595-w","article-title":"Comorbidities and factors influencing frequent gout attacks in patients with gout: a cross-sectional study","volume":"40","author":"Liang","year":"2021","journal-title":"Clin Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1111\/jocn.13918","article-title":"Factors influencing medication adherence in patients with gout: a descriptive correlational study","volume":"27","author":"Chua","year":"2018","journal-title":"J Clin Nurs"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1080\/13696998.2020.1757456","article-title":"Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore","volume":"23","author":"Ling","year":"2020","journal-title":"J Med Econ"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/annrheumdis-2014-206410","article-title":"Comorbidities in patients with gout prior to and following diagnosis: case-control study","volume":"75","author":"Kuo","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/BOR.0b013e3283438e13","article-title":"Risk factors for gout and prevention: a systematic review of the literature","volume":"23","author":"Singh","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.rdc.2014.07.002","article-title":"Gout: a review of nonmodifiable and modifiable risk factors","volume":"40","author":"MacFarlane","year":"2014","journal-title":"Rheum Dis Clin N Am"},{"key":"ref17","unstructured":"Census of population 2020 statistical release 1: demographic characteristics, education, language and religion2021"},{"key":"ref18","unstructured":"About SingHealth polyclinics2020"},{"key":"ref19","volume-title":"OBESITY HPB-MOH clinical practice guidelines 1\/2016","year":"2016"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s13075-021-02701-w","article-title":"Association between female reproductive factors and gout: a nationwide population-based cohort study of 1 million postmenopausal women","volume":"23","author":"Eun","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/ard.2009.109884","article-title":"Menopause, postmenopausal hormone use and risk of incident gout","volume":"69","author":"Hak","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.semarthrit.2020.04.008","article-title":"Gout epidemiology and comorbidities","volume":"50","author":"Singh","year":"2020","journal-title":"Semin Arthritis and Rheum"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1002\/acr.23562","article-title":"Gout severity, socioeconomic status, and work absence: a cross-sectional study in primary care","volume":"70","author":"Bowen-Davies","year":"2018","journal-title":"Arthritis Care Res"},{"key":"ref24","volume-title":"Singapore Census of population 2020, statistical release 1: demographic characteristics, education, language and religion","year":"2021"},{"key":"ref25","volume-title":"The burden of disease in Singapore, 1990\u20132017","year":"2019"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1097\/00004872-200110000-00021","article-title":"Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout","volume":"19","author":"Wurzner","year":"2001","journal-title":"J Hypertens"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152058","article-title":"Sodium-glucose cotransporter 1 inhibition and gout: Mendelian randomisation study","volume":"56","author":"Zhao","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"d8190","DOI":"10.1136\/bmj.d8190","article-title":"Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study","volume":"344","author":"Choi","year":"2012","journal-title":"BMJ"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/2040622315596119","article-title":"The effect of angiotensin II receptor blockers on hyperuricemia","volume":"6","author":"Wolff","year":"2015","journal-title":"Ther Adv Chronic Dis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1097\/HJH.0000000000002359","article-title":"The effects of antihypertensive class on gout in older adults: secondary analysis of the antihypertensive and lipid-lowering treatment to prevent heart attack trial","volume":"38","author":"Juraschek","year":"2020","journal-title":"J Hypertens"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jphs.2017.11.011","article-title":"The uricosuric effects of dihydropyridine calcium channel blockers in vivo using urate under-excretion animal models","volume":"136","author":"Hori","year":"2018","journal-title":"J Pharmacol Sci"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13075-019-1918-7","article-title":"Gout, flares, and allopurinol use: a population-based study","volume":"21","author":"Proudman","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/annrheumdis-2011-200801","article-title":"Patient and provider barriers to effective management of gout in general practice: a qualitative study","volume":"71","author":"Spencer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1136\/ard.2007.071530","article-title":"International survey on the diagnosis and management of gout [3]","volume":"66","author":"Doherty","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cpt.161","article-title":"CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network","volume":"99","author":"Saito","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2217\/pgs.15.125","article-title":"Cost-effectiveness analysis of genotyping for HLA-B\u22175801 and an enhanced safety program in gout patients starting allopurinol in Singapore","volume":"16","author":"Dong","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref38","unstructured":"Allopurinol-induced severe cutaneous adverse reactions and the role of HLA-B*5801 genotyping \u2013 a reminder2019"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41584-021-00657-4","article-title":"Management of gout in chronic kidney disease: a G-CAN consensus statement on the research priorities","volume":"17","author":"Stamp","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"412","DOI":"10.11622\/smedj.2016129","article-title":"Poorly controlled gout: who is doing poorly?","volume":"57","author":"FLA","year":"2016","journal-title":"Singap Med J"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1093\/rheumatology\/keq143","article-title":"Treatment failure gout: failure to treat?","volume":"49","author":"Perry","year":"2010","journal-title":"Rheumatology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2298\/SARH1306333R","article-title":"The efficacy and tolerability of allopurinol dose escalation in patients with gout","volume":"141","author":"Radak-Perovi\u0107","year":"2013","journal-title":"Srp Arh Celok Lek"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1766.2","DOI":"10.1136\/annrheumdis-2020-eular.5823","article-title":"AB0932 factors in achieving target serum uric acid levels in OUTPATIENT gout management in a MALAYSIAN tertiary rheumatology Centre","volume":"79","author":"Mustapha","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1017\/S1463423621000608","article-title":"General practitioners\u2019 knowledge of gout and its management: a case study in Beijing","volume":"22","author":"Liu","year":"2021","journal-title":"Prim Health Care Res Dev"},{"key":"ref45","unstructured":"Gout achieving the management goal2019"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/1756-185X.13103","article-title":"Gout: an Asia-Pacific update","volume":"20","author":"Paul","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/acr.22275","article-title":"Evaluating appropriate use of prophylactic colchicine for gout flare prevention","volume":"66","author":"George","year":"2014","journal-title":"Arthritis Care Res"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/annrheumdis-2023-eular.4049","article-title":"POS0531 evaluation of the knowledge of internal medicine physicians, final-year medical students and rheumatologists regarding the diagnosis and management of gout in Switzerland","volume":"82","author":"Pianta","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1253839\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T17:14:30Z","timestamp":1694106870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1253839\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":48,"alternative-id":["10.3389\/fmed.2023.1253839"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1253839","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"article-number":"1253839"}}